GLPBio

Valorphin

Catalog No.: GC31126Purity:>98.00%
Valorphin is an endogenous hemoglobin β-chain (33-39) fragment with opioid analgesic activity, binds to rat mu-opioid receptor, with an IC50 of 14 nM; Valorphin also shows anti-tumor activity.

Products are for research use only. Not for human use. We do not sell to patients.


Valorphin
Cas No.: 144313-54-2
5mgIn Stock
$110.00
1
10mgIn Stock
$157.00
1
25mgIn Stock
$313.00
1

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

Valorphin is an endogenous hemoglobin β-chain (33-39) fragment with opioid analgesic activity, binds to rat mu-opioid receptor, with an IC50 of 14 nM; Valorphin also shows anti-tumor activity.

Valorphin is a derivative of dihydrovaltrate with opioid analgesic activity, binds to rat mu-opioid receptor, with an IC50 of 14 nM. Valorphin has low affinity for δ-opioid receptor (IC50, 200 nM) and shows no affinity for κ receptor (IC50, >10 μM). Valorphin (>10 μM) decreases spontaneous firing rate of cerebellar rat Purkinje cells[1]. Valorphin (1 μM) treatment 48 h prior to 0.1 μM epirubicin, or 0.1 μM vincristine, or 0.05 μM vincristine, causes 100% tumor cell death[2].

Valorphin exhibits pronounced analgesic activity in mice, rats and rhesus monkeys via s.c, with ED50s of ≤5.2 mg/kg, but barely active after oral administration[1]. Valorphin (1 mg/kg) causes 42% of tumor growth inhibition in female BLRB mice bearing syngeneic mammary carcinoma cells[2].

[1]. Maurer R, et al. Valorphin: a novel chemical structure with opioid activity. Neuropeptides. 1985 Feb;5(4-6):387-90. [2]. Blishchenko EY, et al. Antitumor effect of valorphin in vitro and in vivo: combined action with cytostatic drugs. Cancer Biol Ther. 2005 Jan;4(1):118-24.

Protocol

Cell experiment:

In all series, the cells are incubated for 48 hours beginning with the hour 0. All substances are dissolved in FBS-supplied RPMI-1640 medium. Negative control cells are incubated in the absence of test substances. The reference samples are incubated with epirubicin or Valorphin in the concentrations equivalent to those applied in the experimental seria and for the corresponding time intervals. The effect is evaluated by staining with MTT dye[2].

Animal experiment:

Mice[2]In the basic experiment, 49 mice are randomized in 4 groups: two groups (12 animals each) corresponding to the negative control, the reference group (13 animals) and the experimental group (12 animals). The control and the reference group are treated as in preliminary experiment, the experimental group are injected with the mixture of Valorphin (1 mg/kg) and epirubicin (25 mg/m2), dissolved in 0.9% NaCl solution in distilled water. Three injections (volume 0.2 mL) are made with 6-day intervals. Since no reliable difference in tumor size or lifespan of animals in the two negative control groups are observed, the data obtained in these groups are pooled. At day 20 after the first injection, the size of the tumors are determined. Tumor volumes are calculated, inhibition of tumor growth is determined. Percentages of survival are determined for 1-26 days of treatment. The observation is quitted after the total death of the animals in the negative control group[2].

References:

[1]. Maurer R, et al. Valorphin: a novel chemical structure with opioid activity. Neuropeptides. 1985 Feb;5(4-6):387-90.
[2]. Blishchenko EY, et al. Antitumor effect of valorphin in vitro and in vivo: combined action with cytostatic drugs. Cancer Biol Ther. 2005 Jan;4(1):118-24.

Product Documents

Purity:>98.00%Appearance:A solid

Chemical Properties

CAS No.
144313-54-2
SMILES
Val-Val-Tyr-Pro-Trp-Thr-Gln
Molecular Formula
C44H61N9O11
Molecular Weight
892.01
Solubility
50 mg/mL in DMSO
Storage
Store at -20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for Valorphin

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%